# Metagenomic next-generation sequencing as a diagnostic tool in the clinical routine of an infectious diseases department: a retrospective cohort study

**Authors:** Sven Kalbitz, Jörg Ermisch, Nils Kellner, Olaf Nickel, Stephan Borte, Kathrin Marx, Christoph Lübbert

PMC · DOI: 10.1007/s15010-024-02300-2 · 2024-05-22

## TL;DR

This study evaluates metagenomic sequencing as a diagnostic tool for infectious diseases in routine clinical practice, finding it useful but best used selectively.

## Contribution

Demonstrates the clinical utility of mNGS in routine infectious disease diagnostics beyond special risk populations.

## Key findings

- mNGS detected 66 different microorganisms and viruses in 55 patients, with a 53% positivity rate.
- Most pathogens detected by mNGS were found in patients with immunodeficiency.
- mNGS results led to therapeutic changes in 35% of detected pathogens.

## Abstract

Metagenomic next-generation sequencing (mNGS) of circulating cell-free DNA from plasma is a hypothesis-independent broadband diagnostic method for identification of potential pathogens. So far, it has only been investigated in special risk populations (e.g. patients with neutropenic fever).

To investigate the extent to which mNGS (DISQVER® platform) can be used in routine clinical practice.

We collected whole blood specimens for mNGS testing, blood cultures (BC), and pathogen-specific PCR diagnostics. Clinical data and pathogen diagnostics were retrospectively reviewed by an infectious disease expert panel regarding the adjustment of anti-infective therapy.

In 55 selected patients (median age 53 years, 67% male) with heterogeneous diagnoses, a total of 66 different microorganisms and viruses were detected using mNGS (51% viruses, 38% bacteria, 8% fungi, 3% parasites). The overall positivity rate of mNGS was 53% (29/55). Fifty-two out of 66 (79%) potential pathogens detected by mNGS were found in patients with primary or secondary immunodeficiency. The concordance rates of BC and pathogen-specific PCR diagnostics with mNGS testing were 14% (4/28) and 36% (10/28), respectively (p < 0.001). An additional bacterial pathogen (Streptococcus agalactiae) could only be detected by BC. Therapeutic consequences regarding anti-infective therapy were drawn from 23 pathogens (35% of detections), with 18 of these detections occurring in patients with immunodeficiency.

We conclude that mNGS is a useful diagnostic tool, but should only be performed selectively in addition to routine diagnostics of infectious diseases. The limited number of patients and the retrospective study design do not allow any further conclusions.

## Linked entities

- **Diseases:** immunodeficiency (MONDO:0021094)
- **Species:** Streptococcus agalactiae (taxon 1311)

## Full-text entities

- **Diseases:** primary or secondary immunodeficiency (MESH:D000081207), infectious disease (MESH:D003141), neutropenic fever (MESH:D005334), immunodeficiency (MESH:D007153)
- **Species:** Streptococcus agalactiae (species) [taxon 1311], Homo sapiens (human, species) [taxon 9606], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395]

---
Source: https://tomesphere.com/paper/PMC11289219